Pure Global
NCT05244473

A Safety Study of Brentuximab Vedotin in Participants With HIV

A Phase 1, Single-blind, Dose-escalation Study to Assess the Safety and Tolerability of Brentuximab Vedotin (ADCETRIS®) in Subjects With Human Immunodeficiency Virus (HIV)
Seagen Inc.·Phase 1·ClinicalTrials.gov·drugWithdrawn
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Human Immunodeficiency Virus
Drug/Device/Intervention
brentuximab vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Seagen Inc.
Location
San Francisco,Chicago, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Dec 31, 2022
End date
May 31, 2024
Enrollment
0 participants
Primary outcome

Number of participants with adverse events (AEs),Number of participants with laboratory abnormalities,Number of participants with dose-limiting toxicities (DLTs) by dose level

Summary

This study will test brentuximab vedotin to see if it is safe for people with human
 immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART)
 treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side
 effects of this drug as well. A side effect is anything a drug does to the body besides
 treating the disease.
 
 In this study participants will be assigned randomly to a group. Participants will get either
 brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any
 medicine in it. All participants will keep getting ART during the study.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseasesAsymptomatic human immunodeficiency virus [HIV] infection status
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05244473
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05244473 through Pure Global AI's free database. This Phase 1 trial is sponsored by Seagen Inc. and is currently Withdrawn. The study focuses on Human Immunodeficiency Virus. Target enrollment is 0 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.